These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 620482)

  • 21. Ecogenetic studies of drug acetylation in man and rats.
    Dubbels R; Khoory R; Schloot W
    Acta Anthropogenet; 1981; 5(2):111-8. PubMed ID: 7271997
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Age and dosage dependency in the plasma disposition and the renal clearance of sulfamethazine and its N4-acetyl and hydroxy metabolites in calves and cows.
    Nouws JF; Vree TB; Baakman M; Driessens F; Breukink HJ; Mevius D
    Am J Vet Res; 1986 Mar; 47(3):642-9. PubMed ID: 3963566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics, metabolism, and renal excretion of sulfadimidine and its N4-acetyl and hydroxy metabolites in humans.
    Vree TB; Hekster YA; Nouws JF; Baakman M
    Ther Drug Monit; 1986; 8(4):434-9. PubMed ID: 3824429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Possible optimization of sulphadimidine dosage for acetylator phenotyping.
    Hombhanje F
    Jpn J Pharmacol; 1991 Aug; 56(4):531-4. PubMed ID: 1744992
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N-acetylation and oxidative capacity in aged volunteers determined with sulfamethazine and antipyrine.
    Siegmund W; Franke G; Wulkow R; Hanke W; Thonack R
    Int J Clin Pharmacol Ther Toxicol; 1991 Dec; 29(12):469-73. PubMed ID: 1813431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the sulphadimidine acetylator phenotyping test in patients with reduced renal function.
    Hall S
    Acta Med Scand; 1981; 209(6):505-7. PubMed ID: 7257867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans.
    Lauterburg BH; Smith CV; Todd EL; Mitchell JR
    J Pharmacol Exp Ther; 1985 Dec; 235(3):566-70. PubMed ID: 4078724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acetylation phenotype in hypertensive patients.
    Huang CY; Chu JY; Yen TC
    Gaoxiong Yi Xue Ke Xue Za Zhi; 1992 Jan; 8(1):1-5. PubMed ID: 1548734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polymorphic N-acetylation of sulfamethazine and benzidine by human liver: implication for cancer risk?
    Peters JH; Gordon GR; Lin E; Green CE; Tyson CA
    Anticancer Res; 1990; 10(1):225-9. PubMed ID: 2334132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Catalytic properties and heat stabilities of novel recombinant human N-acetyltransferase 2 allozymes support existence of genetic heterogeneity within the slow acetylator phenotype.
    Hein DW; Doll MA
    Arch Toxicol; 2017 Aug; 91(8):2827-2835. PubMed ID: 28523442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sulfadimidine kinetics in patients with various chronic liver diseases.
    Horváth T; Past T; Par A; Kádas I; Jávor T
    Pol J Pharmacol Pharm; 1988; 40(3):257-64. PubMed ID: 3241767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of sulphadimidine acetylation test in urine and blood for isoniazid phenotyping.
    Nair CR; Gupta RC; Varshneya AK; Malik SK
    Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):646-7. PubMed ID: 6526538
    [TBL] [Abstract][Full Text] [Related]  

  • 33. N-acetylation of the heterocyclic amine batracylin by human liver.
    Stevens GJ; Payton M; Sim E; McQueen CA
    Drug Metab Dispos; 1999 Sep; 27(9):966-71. PubMed ID: 10460792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acetylation phenotype in colorectal carcinoma.
    Ilett KF; David BM; Detchon P; Castleden WM; Kwa R
    Cancer Res; 1987 Mar; 47(5):1466-9. PubMed ID: 3815349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ethanol interaction with drug acetylation in vivo and in vitro.
    Olsen H; Mørland J
    Pharmacol Biochem Behav; 1983; 18 Suppl 1():295-300. PubMed ID: 6634843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acetylator phenotyping of tuberculosis patients using matrix isoniazid or sulphadimidine and its prognostic significance for treatment with several intermittent isoniazid-containing regimens.
    Ellard GA; Gammon PT
    Br J Clin Pharmacol; 1977 Feb; 4(1):5-14. PubMed ID: 843424
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pharmacokinetics of isoniazid.
    Weber WW; Hein DW
    Clin Pharmacokinet; 1979; 4(6):401-22. PubMed ID: 391461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lowering of theophylline clearance by isoniazid in slow and rapid acetylators.
    Samigun ; Mulyono ; Santoso B
    Br J Clin Pharmacol; 1990 May; 29(5):570-3. PubMed ID: 2350534
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of acetylator phenotype on the pharmacokinetics of a new vasodilator antihypertensive, endralazine.
    Reece PA; Cozamanis I; Zacest R
    Eur J Clin Pharmacol; 1982; 23(6):523-7. PubMed ID: 7160421
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple N-acetyltransferases and drug metabolism. Tissue distribution, characterization and significance of mammalian N-acetyltransferase.
    Hearse DJ; Weber WW
    Biochem J; 1973 Mar; 132(3):519-26. PubMed ID: 4724587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.